Amarin Corp Plc (AMRN)

[Biobillionair]

Great chart, as you'll notice it doesn't go out to 2013;). But it does provide the early launch days that Vascepa beats.

Note mo 4 & 5, are the first Lovaza $5 million per month. This equates to 6,750 weekly scripts assuming no stocking fees for Vascepa. Currently Vascepa is at the $5 million per month growth with stocking.

Lovaza's first $10 million month was 10 months out. Vascepa sales with stocking will be well north of $10 million per month come November 2013. As tier 2 effect rolls in the next two months I expect Vascepa will pass the $10 million mark per month.

Williams